ThyGeNEXT联合ThyraMIRv2在甲状腺不确定结节中的盲法真实世界研究
本研究纳入338例细胞学不确定甲状腺结节(258例意义不明的不典型性,80例滤泡性肿瘤)患者样本,均接受MPTXv1(ThyGeNEXT联合ThyraMIR)检测,并进行盲法二次分析评估MPTXv2(ThyraMIRv2)的附加效用。
要点
- MPTXv2在中度阈值灵敏度96%,阳性阈值特异度99%。
- 14%患病率下,MPTXv2阴性预测值99%,阳性预测值89%。
核心结论
- MPTXv1与MPTXv2均表现出稳健性能,假阳性分子结果低。
- 数据提示将MPTXv1及更新的MPTXv2纳入临床实践可改善不确定甲状腺结节的风险分层准确性。
研究设计与样本
- 盲法、真实世界、观察性研究,纳入2016至2020年收集的338例细胞学不确定甲状腺结节患者样本。
- 细胞学诊断包括意义不明的不典型性258例和滤泡性肿瘤80例,样本均有手术结局或临床随访。
- 所有样本接受MPTXv1检测,并进行盲法二次分析评估MPTXv2的附加效用。
- 监测组248例,平均随访30个月。
主要发现
- MPTXv2在中度阈值灵敏度为96%,在阳性阈值特异度为99%。
- 在14%疾病患病率下,MPTXv2中度阈值阴性预测值为99%,阳性阈值阳性预测值为89%。
- MPTXv2归入中度风险组的患者少于MPTXv1,差异有统计学意义(p < .001)。
- 以手术切除为金标准,MPTXv2的曲线下面积显著大于MPTXv1(p = .028),准确性更高。
关键数值与推荐
- MPTXv2中度阈值灵敏度96%,阳性阈值特异度99%。
- 14%患病率下,MPTXv2中度阈值阴性预测值99%,阳性阈值阳性预测值89%。
- MPTXv2与MPTXv1中危组患者数差异p < .001,AUC差异p = .028。
临床怎么用
- 对于细胞学不确定的甲状腺结节,可结合ThyGeNEXT联合ThyraMIRv2进行分子风险分层。
- MPTXv2的高阴性预测值有助于识别可安全随访的低风险患者。
- MPTXv2较MPTXv1减少中危组分类并提高准确性,可优化临床管理决策。
局限性
- 研究为观察性设计,可能存在选择偏倚。
- 监测组随访时间平均30个月,可能不足以捕捉长期结局。
- 样本来自单一医疗网络,外推性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular analysis of fine-needle aspiration biopsies (FNAB) improves the diagnostic accuracy of cytologically indeterminate thyroid nodules (ITNs). Recently, the use of MPTXv2 has been shown to further improve the accuracy of risk stratification of ITNs. METHODS: A total of 338 patient samples with atypia of undetermined significance (n = 258) or follicular neoplasm (n = 80) cytology diagnosis and corresponding surgical outcomes or clinical follow-up, collected between 2016 and 2020 were included [Correction added on 19 June 2024, after first online publication: In the preceding sentence, the n values 260 and 78 have been changed to 258 and 80, respectively.]. All samples underwent multiplatform testing (MPTXv1), which includes an oncogene panel (ThyGeNEXT®) plus a microRNA risk classifier (ThyraMIR®). A blinded, secondary analysis was performed to assess the added utility of MPTXv2 (ThyraMIR®v2). The average length of follow-up for the surveillance group (n = 248) was 30 months. RESULTS: Sensitivity at moderate threshold was 96% and specificity at positive threshold was 99% for MPTXv2. At 14% disease prevalence, the negative predictive value at the moderate threshold was 99% and the positive predictive value at the positive threshold was 89% for MPTXv2. MPTXv2 had fewer patients classified into the moderate-risk group than MPTXv1, which was statistically significant (p < .001). Using surgical resection, the gold standard for outcomes, MPTXv2 showed a statistically greater area under the curve (p = .028) than MPTXv1, demonstrating greater accuracy for MPTXv2. CONCLUSION: Both test versions demonstrated robust performance with low false-positive molecular results. Data suggest that incorporation of MPTXv1, and more recently MPTXv2, into clinical practice within our healthcare network resulted in improved accuracy of ITN risk stratification.
引用
- Verma T, Marshall C, Dantey KE, et al. The role of the ThyGeNEXT oncogene panel used in combination with the expanded miRNA panel ThyraMIRv2 in Indeterminate thyroid nodules: A large, blinded, real-world, observational study. Cancer Cytopathol. 2024. PMID: 38814813. doi:10.1002/cncy.22829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。